|
Fujitsu Supports Hospitals with New Clinical Trial Solution, "tsClinical DDworks21/Trial Site"
TOKYO, Jan 24, 2019 - (JCN Newswire) - Fujitsu has enhanced its clinical trial-supporting Fujitsu Life Science Solution tsClinical DDworks21 series with the launch of the SaaS solution tsClinical DDworks21/Trial Site. The new solution, available from today, provides hospitals and other clinical trial sites in Japan with shared cloud-based control of documents conventionally exchanged in paper form between pharmaceutical companies developing new drugs and the sites conducting the clinical trials.
 | | Diagram of tsClinical DDworks21/Trial Site flow |
 | |
Clinical trial documents are records that prove a trial's reliability, so they are required by law to be stored long-term under strict control. Most clinical trial sites use paper records, and the exchange and storage of these documents remains labor intensive. After new drug approval, the documents must be managed properly for five years in Japan (in Europe, for a minimum of 25 years), a lengthy requirement that places a burden on hospital staff. The Trial Site solution reduces this operational burden and contributes to higher efficiency and lower costs. By adding this solution to the tsClinical DDworks21 series lineup, Fujitsu expands its business in the clinical trial field and contributes to the comprehensive optimization of clinical trials.
Background
New drug development is generally said to take 10 years and cost between 20 to 30 billion yen in Japan. In total, pharmaceutical companies in Japan spend 1.4 trillion yen annually on drug development, and lowering the cost of clinical trials represents a significant challenge.
In recent years, various industries are increasingly going paperless by digitizing documents. In the medical field, while pharmaceutical companies, particularly in new drug development processes, are transitioning toward digitization, most clinical trial sites still operate by affixing seal impressions on paper documents in clinical trials. As a result, the printing of enormous quantities of documents generated during clinical trials, filing tasks, and securing storage space remain a significant issue. For pharmaceutical company staff (monitors) who repeatedly visit clinical trial sites to deliver and receive paper documents and check on storage conditions, reducing the workload associated with clinical trials is an urgent issue.
To overcome these challenges, Fujitsu drew on its know-how in operational support for clinical trials gained through the development of the tsClinical DDworks21 series to create a new solution for clinical trial sites. At hospitals and other clinical trial sites, documents are managed as electronic originals on the cloud, and processes related to this management are streamlined and the quality is improved.
Prior to launching this solution, Fujitsu conducted a field trial with National Cancer Center Hospital East and National Cancer Center Hospital. The trial verified higher efficiency and proper control of digitized exchange and storage of clinical trial documents as well as Institutional Review Board (IRB) operations.
Main Features of the Solution
1. Reliable document management
When clinical trial documents are saved as part of the electronic exchange with pharmaceutical companies and during hospital workflow, they are managed by the automatic generation of appropriate folders based on meta data, such as the time and date they were created and the name of the trial. This enables reliable folder management and version number management for each study as well as easy access for the most recent data. Furthermore, paperless operations means the enormous volume of filing and storage space required at clinical trial sites is reduced, so costs go down.
2. Higher efficiency of clinical trial operations through a shared platform
Staff at clinical trial sites and pharmaceutical companies conducting clinical trials will use a specialized website to access data stored in a cloud environment, so operations previously handled manually at clinical trial sites by Clinical Research Coordinators (CRCs), such as printing and mailing paper documents, will be streamlined. This solution is also expected to reduce the workload of monitors from pharmaceutical companies associated with checking on document storage conditions at clinical trial sites. This will contribute to invigorating clinical trials in Japan and resolving issues affecting society, such as Japan's drug lag and device lag(1).
Comment from Dr. Toshihiko Doi, Deputy Director of National Cancer Center Hospital East
In this field trial, we successfully identified how to reduce operational burdens and increase efficiency for trial administrators by utilizing document digitization and systemized operation of process management. I hope this solution will be widely used by clinical trial sites and eventually link to tsClinical DDworks 21, which is used by many pharmaceutical companies. I have high expectations that Fujitsu will play a leading role as pharmaceutical companies and clinical trial sites share information on their respective needs and create a new platform.
Pricing and Availability
http://www.acnnewswire.com/topimg/Low_PricingtsClinicalDDworks21.jpg
(1) Drug lag and device lag The wait period of a pharmaceutical product or medical device approved overseas, before it is approved in Japan.
Contact:Fujitsu Limited
Public and Investor Relations
Tel: +81-3-3215-5259
URL: www.fujitsu.com/global/news/contacts/
Source: Fujitsu Ltd
Sectors: Cloud & Enterprise
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network. |
Latest Release
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
| 
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
| 
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
| 
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
|
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
| 
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Apr 18, 2024 10:53 JST
| 
All-New Triton Confirmed as First Double-Cab Pickup Truck to Achieve 2024 Five-Star ANCAP Safety Rating
Apr 18, 2024 09:22 JST
|
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
Apr 17, 2024 16:17 JST
| 
Honda Unveils Next-generation EV Series for China
Apr 17, 2024 12:15 JST
| 
Lexus presents Time at the 2024 Milan Design Week
Apr 16, 2024 18:49 JST
| 
Mitsubishi Corporation Announces Participation in a DAC Project in Louisiana, USA
Apr 16, 2024 14:36 JST
|
New circuit challenge for TOYOTA GAZOO Racing
Apr 15, 2024 17:21 JST
|
TOYOTA GAZOO Racing back on asphalt for Croatian challenge
Apr 12, 2024 19:36 JST
|
Heidelberg Materials North America Announces Latest Milestone in Edmonton CCUS Project
Apr 12, 2024 14:39 JST
|
MHIAEL Completes Expansion of the its Nagasaki Plant for Manufacture of Aero Engine Combustors
Apr 11, 2024 18:08 JST
|
Mitsubishi Shipbuilding Acquires Approval in Principle (AiP) from Classification Society ClassNK for Ammonia Fuel Supply System (AFSS)
Apr 11, 2024 17:50 JST
|
DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission
Apr 11, 2024 15:10 JST
|
Mitsubishi Corporation Announces Completion of Capital Raise by Nexamp
Apr 11, 2024 13:07 JST
|
Mitsubishi Shipbuilding Receives Order for Ammonia Fuel Supply System for Ammonia-Powered Marine Engine
Apr 10, 2024 16:55 JST
| 
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
Apr 10, 2024 13:36 JST
|
More Latest Release >>
|